| Symbol
| EPCAM
| contributors: mct/npt/pgu - updated : 21-06-2023
|
| HGNC name
| epithelial cell adhesion molecule
|
| HGNC id
| 11529
|
| Other morbid association(s)
|
| Type | Gene Modification | Chromosome rearrangement | Protein expression | Protein Function
|
|---|
| tumoral
|
|
| --over
|
| |
in esophageal carcinoma, with long survival | | tumoral
|
|
| --over
|
| |
in retinoblastoma | | tumoral
|
|
| --over
|
| |
in colorectal and lung carcinomas | | tumoral
| germinal mutation
| deletion
|
|
|
contributing to germline MLH1 hypermethylation, and to Lynch syndrome  | | tumoral
|
|
| --over
|
| |
in gastric cancer tissues and cell lines | | tumoral
|
|
| --over
|
| |
is the unfavorable predictor for the shorter overall survival (OS) and disease-free survival (DFS) for Hepatocellular carcinoma (HCC) patients | | constitutional
|
|
|
| loss of function
| |
loss of EPCAM may cause the reduction and mislocalization of proteins that compose adherens junctions partly via the downregulation of nectin 1 in the intestines | |
Variant & Polymorphism
| 
| |
Candidate gene
| Marker
| significant prognostic factor in pancreatic cancer patients by suppressing cell activity, and its expression was found to be related to the suppression of pancreatic cancer cell activity and the good prognosis in pancreatic cancer patients receiving the curative resection | |
marker highly expressed in carcinomas and showing a strong correlation with poor cancer prognosis | Therapy target
|
|
| System | Type | Disorder | Pubmed |
|---|
| cancer | eye | | |
| target for therapy in retinoblastoma | | cancer | digestive | stomach | |
| potential value of EPCAM in the therapy of gastric cancer in clinic |
| | |
|
| EpCAM-/- embryos become nonviable because of placental insufficiency resulting from attenuated development of the labyrinthine layer, a process that involves invasion of fetal elements into the maternal decidua |